biostudies-literatureUnknown6(5)Bakht D<h4>Background</h4>Venous thromboembolism (VTE) is a serious complication in cancer patients, with malignancy increasing the risk significantly. Direct oral anticoagulants (DOACs) have emerged as a convenient alternative to traditional therapies, though optimal dosing remains uncertain.<h4>Methods</h4>We performed a systematic review and meta-analysis on three studies. A comprehensive literature search was performed on PubMed, Embase, the Cochrane Library, and ScienceDirect till April 2025. Analysis was carried out on RevMan 5.4. The risk of bias was assessed via RoB 2.0.<h4>Results</h4>A total of three studies with 2416 participants were identified, including 1495 patients in the reduced-dose group and 1232 patients in the full-dose group. No significant difference was observed in recurreEJHaeme70155https://www.ebi.ac.uk/biostudies/studies/S-EPMC12459301biostudies-literatureReduced Versus Full-Dose Direct Oral Anticoagulants for Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis.PMC12459301Dad ANaqvi MZBakht DTahir MGulzar ENasir ZKhalil MArham MBakht KHaris HMTareen HAwais MNRashid ZAmir MfalseReduced Versus Full-Dose Direct Oral Anticoagulants for Venous Thromboembolism in Cancer Patients: A Systematic Review and Meta-Analysis.<h4>Background</h4>Venous thromboembolism (VTE) is a serious complication in cancer patients, with malignancy increasing the risk significantly. Direct oral anticoagulants (DOACs) have emerged as a convenient alternative to traditional therapies, though optimal dosing remains uncertain.<h4>Methods</h4>We performed a systematic review and meta-analysis on three studies. A comprehensive literature search was performed on PubMed, Embase, the Cochrane Library, and ScienceDirect till April 2025. Analysis was carried out on RevMan 5.4. The risk of bias was assessed via RoB 2.0.<h4>Results</h4>A total of three studies with 2416 participants were identified, including 1495 patients in the reduced-dose group and 1232 patients in the full-dose group. No significant difference was observed in recurre2025-01-01T00:00:00Z2025 Oct2026-06-03T20:14:33.481Z2026-05-30T03:06:44.306ZS-EPMC124593014100025310.1002/jha2.70155